Experienced in Heart Failure with Preserved Ejection Fraction (HFpEF)

Michel Burnier

Lausanne, VD, CH 
Experienced in Heart Failure with Preserved Ejection Fraction (HFpEF)
Lausanne, VD, CH 
OverviewLocationsClinical Research

Overview

Michel Burnier practices in Lausanne, Switzerland. Mr. Burnier is rated as an Experienced expert by MediFind in the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). His top areas of expertise are Hypertension, Chronic Kidney Disease, Calcinosis, Kidney Transplant, and Endoscopy.

His clinical research consists of co-authoring 473 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Heart Failure with Preserved Ejection Fraction (HFpEF).

Gender
Male

Locations

Lausanne, VD, Switzerland
Other Locations
Geneve, GE, Switzerland
St Légier, Switzerland
Le Vaud, VD, Switzerland
Bern, BE, Switzerland
Aesch, LU, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Effect of Acute Hyperglycemia on Renal Tissue Oxygenation as Measured By BOLD-MRI in Individuals With Impaired Glucose Tolerance and Controls
Effect of Acute Hyperglycemia on Renal Tissue Oxygenation as Measured By BOLD-MRI in Individuals With Impaired Glucose Tolerance and Controls
Enrollment Status: Completed
Publish Date: July 31, 2019
Intervention Type: Other
Study Phase: Early Phase 1
Effects of the SGLT2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-diabetic Subjects
Effects of the SGLT2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-diabetic Subjects
Enrollment Status: Completed
Publish Date: July 30, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Benazepril (ATC N° C09AA07) in the Treatment of Persistent Renal Dysfunction in Pre-eclamptic Women
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Benazepril (ATC N° C09AA07) in the Treatment of Persistent Renal Dysfunction in Pre-eclamptic Women
Enrollment Status: Completed
Publish Date: May 01, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

472 Total Publications

The gut as a mediator of environmental harm: unveiling microbial pathways in climate-related disease. Author's reply.
The gut as a mediator of environmental harm: unveiling microbial pathways in climate-related disease. Author's reply.
Journal: Polish archives of internal medicine
Published: August 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Burnier's expertise for a condition
ConditionClose
View All 35 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile